BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

806 related articles for article (PubMed ID: 18399169)

  • 1. [Monoclonal antibody against brain derived neurotrophic factor inhibits myeloma growth and angiogenesis in the xenograft NOD/SCID animal model].
    Wang YD; Hu Y; Zhang L; Huang J; Sun CY
    Zhonghua Xue Ye Xue Za Zhi; 2007 Oct; 28(10):659-63. PubMed ID: 18399169
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumor effect of anti-brain derived neurotrophic factor monoclonal antibody in human multiple myeloma xenograft animal model.
    Wang YD; Hu Y; Huang J; Zhang L; Sun CY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Oct; 16(5):1069-72. PubMed ID: 18928597
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of brain-derived neurotrophic factor as a novel angiogenic protein in multiple myeloma.
    Hu Y; Wang YD; Guo T; Wei WN; Sun CY; Zhang L; Huang J
    Cancer Genet Cytogenet; 2007 Oct; 178(1):1-10. PubMed ID: 17889702
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined anti-fetal liver kinase 1 monoclonal antibody and continuous low-dose doxorubicin inhibits angiogenesis and growth of human soft tissue sarcoma xenografts by induction of endothelial cell apoptosis.
    Zhang L; Yu D; Hicklin DJ; Hannay JA; Ellis LM; Pollock RE
    Cancer Res; 2002 Apr; 62(7):2034-42. PubMed ID: 11929822
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Study of brain-derived neurotrophic factor activating TrkB signaling cascades in the pathogenesis of multiple myeloma].
    Sun CY; Hu Y; Guo T; Huang J; Zhang L; Chu ZB
    Zhonghua Xue Ye Xue Za Zhi; 2008 Apr; 29(4):238-42. PubMed ID: 18843977
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Effect of brain-derived neurotrophic factor in human myeloma cells on angiogenesis].
    Hu Y; Wu T; Wang YD; He WJ
    Zhonghua Xue Ye Xue Za Zhi; 2005 Oct; 26(10):602-6. PubMed ID: 16532969
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-CD7 antibody and immunotoxin treatment of human CD7(+)T-cell leukaemia is significantly less effective in NOD/LtSz-scid mice than in CB.17 scid mice.
    Flavell DJ; Warnes SL; Noss AL; Flavell SU
    Br J Cancer; 2000 Dec; 83(12):1755-61. PubMed ID: 11104577
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Establishment and application of engrafted tumor models with humanized tumor blood vessel].
    Ran YL; Zhong X; Hu H; Yu L; Lou JN; Yang ZH
    Ai Zheng; 2006 Nov; 25(11):1323-8. PubMed ID: 17094895
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2.
    Kunkel P; Ulbricht U; Bohlen P; Brockmann MA; Fillbrandt R; Stavrou D; Westphal M; Lamszus K
    Cancer Res; 2001 Sep; 61(18):6624-8. PubMed ID: 11559524
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systemic anti-hepatocyte growth factor monoclonal antibody therapy induces the regression of intracranial glioma xenografts.
    Kim KJ; Wang L; Su YC; Gillespie GY; Salhotra A; Lal B; Laterra J
    Clin Cancer Res; 2006 Feb; 12(4):1292-8. PubMed ID: 16489086
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model.
    LeBlanc R; Catley LP; Hideshima T; Lentzsch S; Mitsiades CS; Mitsiades N; Neuberg D; Goloubeva O; Pien CS; Adams J; Gupta D; Richardson PG; Munshi NC; Anderson KC
    Cancer Res; 2002 Sep; 62(17):4996-5000. PubMed ID: 12208752
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neutrophils contribute to the biological antitumor activity of rituximab in a non-Hodgkin's lymphoma severe combined immunodeficiency mouse model.
    Hernandez-Ilizaliturri FJ; Jupudy V; Ostberg J; Oflazoglu E; Huberman A; Repasky E; Czuczman MS
    Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5866-73. PubMed ID: 14676108
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Establishment of multiple myeloma mouse models expressing brain derived neurotrophic factor].
    Wang YD; Hu Y; Zhang L; Huang J; Sun CY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Oct; 15(5):967-72. PubMed ID: 17956671
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer.
    Landen CN; Lu C; Han LY; Coffman KT; Bruckheimer E; Halder J; Mangala LS; Merritt WM; Lin YG; Gao C; Schmandt R; Kamat AA; Li Y; Thaker P; Gershenson DM; Parikh NU; Gallick GE; Kinch MS; Sood AK
    J Natl Cancer Inst; 2006 Nov; 98(21):1558-70. PubMed ID: 17077358
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-angiogenic effects and regression of localized murine AML produced by anti-VEGF and anti-Flk-1 antibodies.
    Reichert F; Barak V; Tarshis M; Prindull G; Tarshis E; Ben-Ishay Z
    Eur J Haematol; 2005 Jul; 75(1):41-6. PubMed ID: 15946309
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor effects of a monoclonal antibody that binds anionic phospholipids on the surface of tumor blood vessels in mice.
    Ran S; He J; Huang X; Soares M; Scothorn D; Thorpe PE
    Clin Cancer Res; 2005 Feb; 11(4):1551-62. PubMed ID: 15746060
    [TBL] [Abstract][Full Text] [Related]  

  • 17. p38alpha-selective MAP kinase inhibitor reduces tumor growth in mouse xenograft models of multiple myeloma.
    Medicherla S; Reddy M; Ying J; Navas TA; Li L; Nguyen AN; Kerr I; Hanjarappa N; Protter AA; Higgins LS
    Anticancer Res; 2008; 28(6A):3827-33. PubMed ID: 19189670
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A neutralizing anti-fibroblast growth factor (FGF) 8 monoclonal antibody shows anti-tumor activity against FGF8b-expressing LNCaP xenografts in androgen-dependent and -independent conditions.
    Maruyama-Takahashi K; Shimada N; Imada T; Maekawa-Tokuda Y; Ishii T; Ouchi J; Kusaka H; Miyaji H; Akinaga S; Tanaka A; Shitara K
    Prostate; 2008 May; 68(6):640-50. PubMed ID: 18213631
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-VEGF antibody in experimental hepatoblastoma: suppression of tumor growth and altered angiogenesis.
    McCrudden KW; Hopkins B; Frischer J; Novikov A; Huang J; Kadenhe A; New T; Yokoi A; Yamashiro DJ; Kandel JJ; Middlesworth W
    J Pediatr Surg; 2003 Mar; 38(3):308-14; discussion 308-14. PubMed ID: 12632340
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activating Fc receptors are required for antitumor efficacy of the antibodies directed toward CD25 in a murine model of adult t-cell leukemia.
    Zhang M; Zhang Z; Garmestani K; Goldman CK; Ravetch JV; Brechbiel MW; Carrasquillo JA; Waldmann TA
    Cancer Res; 2004 Aug; 64(16):5825-9. PubMed ID: 15313926
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.